Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and maintains $60 price ta...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this yearARCT-810 to exp...
Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Vid...
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). ...
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, ...
ARCT-032 is safe and well tolerated with no serious adverse events (SAEs) in 36 study participants, including 4 adults with cys...
Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung ...
